Welcome to Abcentra™

We are a clinical-stage biopharmaceutical company developing first-in-class therapeutics that target oxidized LDL, an anti-inflammatory approach for treating cardiovascular disease.

Our pipeline focuses on treating patient populations with substantial residual risk of accelerated atherosclerosis, cardiovascular events, and valve disease as a result of chronic inflammation.

Bullseye Icon

Target Oxidized Lipoproteins

Our products target oxidized lipoproteins, such as low-density lipoprotein (oxLDL) and lipoprotein(a). Oxidized lipoproteins are potent inflammatory mediators that are implicated in several inflammatory diseases.

How It Works

Antibody icon

Treat Inflammatory Disease

Our clinical and preclinical programs are focused on addressing unmet needs in inflammatory diseases including plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis.

Learn More

Recent News

Patient lying in bed in background out of focus, IV drip in forground

Abcentra Announces First Patients Dosed with Orticumab in Clinical Trial Evaluating Blockade of Oxidized LDL in Psoriasis with Elevated Cardiometabolic Risk

Abcentra LLC announces that the first patients have been dosed in its multi-center phase 2 trial assessing the safety and activity of orticumab.
timothy wright board of directors

Timothy Wright Joins Board of Directors

Experienced drug developer and pharma executive, Dr. Timothy Wright, has joined the Abcentra™’s Board of Directors.
Shot of businesspeople having a meeting in an office

Abcentra™ Names Kevin Bacon Chief Executive Officer

Experienced Industry Leader Elevates Research and Development Capabilities, Joins Company At An Important Development Juncture